• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 1, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Scientists show we don’t need horses to treat diphtheria

Bioengineer by Bioengineer
January 21, 2020
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Research funded by PETA Science Group breaks new ground with animal-free antibodies

IMAGE

Credit: PETA India

London – A project taking the first steps towards ending the use of horses to treat diphtheria has succeeded.

Funded by the PETA International Science Consortium Ltd. and carried out at the Institute of Biochemistry, Biotechnology, and Bioinformatics at the Technische Universität Braunschweig in Germany, the project created human antibodies capable of blocking the poisonous toxin that causes diphtheria. The results were published Friday in Scientific Reports (a Nature research journal).

Diphtheria is a potentially deadly infectious disease causing severe respiratory distress and damage to vital organs and is a significant human health burden. For more than 100 years, the main method of producing the antitoxin to treat it has been to inject horses repeatedly with the diphtheria toxin and then drain them of huge amounts of their blood in order to collect the antibodies that their immune systems produce to fight the disease. This animal-derived antitoxin has the potential to cause serious allergic reactions in humans, and global health authorities report having difficulty acquiring sufficient stockpiles of these antitoxins to respond quickly to diphtheria outbreaks.

Inspections of facilities where horses are used to produce animal-derived antitoxins have found widespread neglect of animal welfare regulations, with horses confined to filthy, severely crowded enclosures and suffering from anaemia, diseased hooves, eye abnormalities, infections, parasites, and malnutrition.

Rather than using horses, the researchers involved in this project used human blood cells to create human antibodies that block the diphtheria toxin. The Science Consortium is now working with its research partners to ensure that the non-animal antitoxin is developed into a medicine that will be used to treat this menacing disease more reliably and safely without causing a single horse to suffer.

“Thousands of horses worldwide are forced to endure cruel treatment for the production of many different types of drugs, not just diphtheria antitoxin,” says Jeffrey Brown, adviser to the PETA International Science Consortium and co-author of the paper. “Solid science has now given these horses a way out of this suffering.”

###

The PETA International Science Consortium Ltd. works to accelerate the development, validation, and global implementation of animal-free testing. It was established in 2012 to coordinate the scientific and regulatory expertise of its members – PETA US, PETA UK, PETA Germany, PETA India, PETA Netherlands, PETA France, PETA Asia, and PETA Australia. The Science Consortium and its members have donated millions of pounds towards helping to reduce and replace animal use.

For more information, please visit PISCLtd.org.uk.

Media Contact
Tasgola Bruner
[email protected]
404-907-4172

Related Journal Article

http://dx.doi.org/10.1038/s41598-019-57103-5

Tags: Cell BiologyDisease in the Developing WorldHealth CareInfectious/Emerging DiseasesMedicine/HealthPharmaceutical SciencePublic HealthVaccines
Share12Tweet8Share2ShareShareShare2

Related Posts

Tracking Tumor DNA During Gastric Cancer Treatment

Tracking Tumor DNA During Gastric Cancer Treatment

August 1, 2025
Heparan Sulfate Protein Improves MPS IIIB Symptoms

Heparan Sulfate Protein Improves MPS IIIB Symptoms

August 1, 2025

Rising Use of Cannabis for Chronic Health Issues Amid Ongoing Uncertainty

August 1, 2025

March5 Drives Trim28 Degradation to Preserve β-Cells

August 1, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    37 shares
    Share 15 Tweet 9
  • Sustainability Accelerator Chooses 41 Promising Projects Poised for Rapid Scale-Up

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Melanthiaceae Genomes Reveal Giant Genome Evolution Secrets

Tracking Tumor DNA During Gastric Cancer Treatment

Heparan Sulfate Protein Improves MPS IIIB Symptoms

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.